Related Experiment Video

Updated: Jun 20, 2026

Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

[Obesity in pediatric anesthesia]

Claudia Höhne1, Johanna Ulrici, Jochen M Strauss

  • 1Klinik und Poliklinik für Anästhesiologie und Intensivtherapie des Universitätsklinikums Leipzig im Frauen-Kind-Zentrum als Oberärztin. claudia.hoehne@medizin.uni-leipzig.de

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
|September 15, 2009
PubMed

Insights

Overweight and obese children undergoing anesthesia face increased risks. This review covers obesity causes, physiological changes, and anesthetic management strategies to improve patient safety.

Area of Science:

  • Pediatric Anesthesiology
  • Public Health
  • Pediatric Endocrinology

Context:

  • Rising prevalence of pediatric overweight and obesity.
  • Increased perioperative risks in anesthetized children.
  • Need for specialized anesthetic care in pediatric obesity.

Purpose:

  • To define and explore causes of childhood obesity.
  • To detail pathophysiological changes associated with pediatric obesity.
  • To focus on anesthesiological management and potential complications in obese children.

Summary:

  • Discusses the definition and etiology of pediatric obesity.
  • Explains relevant pathophysiological alterations in obese children.
  • Highlights anesthesiological considerations and complications during procedures.

Impact:

  • Informs anesthesiologists on managing obese pediatric patients.
  • Aims to reduce perioperative morbidity and mortality in this population.
  • Contributes to improved clinical guidelines for pediatric anesthesia.

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...